MeiraGTx Holdings PLC
NASDAQ:MGTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
AB&Company Co Ltd
TSE:9251
|
JP |
|
M
|
Mystic Electronics Ltd
BSE:535205
|
IN |
|
G
|
Getty Copper Inc
XTSX:GTC
|
CA |
|
M
|
M Vest Water AS
OSE:MVW
|
NO |
|
Tyro Payments Ltd
ASX:TYR
|
AU |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
MeiraGTx Holdings PLC
NASDAQ:MGTX
|
613.3m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD |
Loading...
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
MeiraGTx Holdings PLC
Glance View
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 287 full-time employees. The company went IPO on 2018-06-08. The firm is focused on three areas of unmet medical needs, including inherited retinal diseases (IDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. The Company’s products pipeline includes AAV-RPGR, which is for the treatment of x-linked retinitis pigmentosa (XLRP); AAV-hAQP1, which is for the treatment of grade two/three radiation-induced xerostomia; AAV-GAD, is for the treatment of Parkinson’s disease, and AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia (ACHM). The firm has six programs in clinical development, including Phase I/Il clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa and RPE65-Deficiency, and Phase I clinical trials for radiation-induced xerostomia (RIX), and a Parkinson’s program that has completed a Phase II trial with published data.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for MeiraGTx Holdings PLC is 41%, which is above its 3-year median of 22.9%.
Over the last 1 years, MeiraGTx Holdings PLC’s Gross Margin has increased from -7.7% to 41%. During this period, it reached a low of -7.7% on Sep 30, 2024 and a high of 41% on Oct 30, 2025.
